title: [Malignant ovarian germ cell tumours: a trial of 36 cases].
abstract: OBJECTIVE
  With personal results and a review of the literature, we report the eventual interest of surgical staging in malignant ovarian germ cell tumours.
  
  
  METHODS
  This was a retrospective study of 36 patients (21.5-[8-61]) with malignant ovarian germ cell tumours between January 1984 and December 2004. There were 4 groups: no 1--dysgerminoma only, no 2--immature teratoma, no 3--malignant ovarian germ cell tumours with secretion. All the patients had a minimal follow up of 18 months after treatment. We reported conservative or non-conservative surgery, if surgical staging was made and description of eventual neoadjuvant or adjuvant chemotherapies and finally the recurrences and deaths.
  
  
  RESULTS
  Stages of FIGO were: group 1--IA n=2, IC n=2, IIB n=1, IIIA n=2, IIIC n=3; group 2--IA n=3 (G1, G2, G2), IC n=1 (G3); group 3--IA n=8, IC n=4, IIA n=1, IIIA n=1, IIIB n=3, IIIC n=5. Three patients had neoadjuvant chemotherapy. All the patients had cytoreductive surgery (conservative surgery n=31) with staging in 15 cases. Twenty-six patients had adjuvant chemotherapy. Five years global survival was 92%.
  
  
  CONCLUSIONS
  Surgery in a young patient with malignant ovarian germ cells tumours must be conservative (adnexectomy) (preserving fertility and because of good prognostic). In case of stage IA with part of dysgerminoma and/or immature teratoma and/or embryonal carcinoma certified by surgical staging, strict follow up could be organized (clinic, radiology, AFP, HCG). In case of more than stage IA, chemotherapy is indicated after conservative surgery and surgical staging.
authors.affiliation: Clinique de gynécologie, Hôpital Jeanne-de-Flandre, CHRU de Lille, Lille cedex, France.
authors.forename: A
authors.initials: A
authors.lastname: Gueye
authors.forename: F
authors.initials: F
authors.lastname: Narducci
authors.forename: M-C
authors.initials: MC
authors.lastname: Baranzelli
authors.forename: P
authors.initials: P
authors.lastname: Collinet
authors.forename: O
authors.initials: O
authors.lastname: Farine
authors.forename: C
authors.initials: C
authors.lastname: Fournier
authors.forename: D
authors.initials: D
authors.lastname: Vinatier
authors.forename: E
authors.initials: E
authors.lastname: Leblanc
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002648:Child; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000517:prevention & control*; D008875:Middle Aged; D009367:Neoplasm Staging; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D010052:Ovariectomy / Q000379:methods*; D011379:Prognosis; D012189:Retrospective Studies; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents